Showing results (101-110 of 128) with videos related to

Sort By:
Pageof 13
Vaccine|November 1, 2011
Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaquesIzabela Bialuk, Stephen Whitney, Vibeke Andresen, et al.
Vaccine|May 20, 2008
Comparative study of Tat vaccine regimens in Mauritian cynomolgus and Indian rhesus macaques: influence of Mauritian MHC haplotypes on susceptibility/resistance to SHIV(89.6P) infectionRuth H Florese, Roger W Wiseman, David Venzon, et al.
Virology|December 3, 2014
HIV-1 CD4-induced (CD4i) gp120 epitope vaccines promote B and T-cell responses that contribute to reduced viral loads in rhesus macaquesMichael A Thomas, Iskra Tuero, Thorsten Demberg, et al.
International Journal of Molecular Sciences|February 6, 2020
Comparison of Eight Technologies to Determine Genotype at the UGT1A1 (TA)<sub>n</sub> Repeat Polymorphism: Potential Clinical Consequences of Genotyping Errors?Tristan M Sissung, Roberto H Barbier, Douglas K Price, et al.
Journal of Virology|January 18, 2013
Antibodies to gp120 and PD-1 expression on virus-specific CD8+ T cells in protection from simian AIDSMonica Vaccari, Rabih Halwani, L Jean Patterson, et al.
The Oncologist|March 26, 2017
A Phase Ib Study of Sorafenib (BAY 43-9006) in Patients with Kaposi SarcomaThomas S Uldrick, Priscila H Gonçalves, Kathleen M Wyvill, et al.
Plos Pathogens|August 13, 2015
Mucosal B Cells Are Associated with Delayed SIV Acquisition in Vaccinated Female but Not Male Rhesus Macaques Following SIVmac251 Rectal ChallengeIskra Tuero, Venkatramanan Mohanram, Thomas Musich, et al.
Journal of Virology|March 31, 2006
Systemic immunization with an ALVAC-HIV-1/protein boost vaccine strategy protects rhesus macaques from CD4+ T-cell loss and reduces both systemic and mucosal simian-human immunodeficiency virus SHIVKU2 RNA levelsRanajit Pal, David Venzon, Sampa Santra, et al.
Molecular Cancer Therapeutics|December 21, 2013
Cancer-associated CD43 glycoforms as target of immunotherapyFranca Maria Tuccillo, Camillo Palmieri, Giuseppe Fiume, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 7, 2012
Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemiaCody J Peer, Tristan M Sissung, Aerang Kim, et al.
Pageof 13